What Pharmanovia does

Pharmanovia is a global specialty pharmaceutical company headquartered in Basildon, UK, founded in 2013 by Dr. Amit Patel (originally as Atnahs, rebranded to Pharmanovia in 2021) and backed by private equity firm Triton since 2019. The company operates a two-pronged model: it manages a portfolio of more than 30 trusted established pharmaceutical brands (including Valium, Inderal, Zestril, Synacthen, Naprosyn, Famvir and Rocaltrol) across endocrinology, neurology, cardiovascular and oncology therapy areas, while simultaneously in-licensing and commercialising innovative specialty medicines such as Korjuny (catumaxomab) for malignant ascites, abaloparatide (TYMLOS) for osteoporosis, Sunosi for narcolepsy and obstructive sleep apnoea, GHRYVELIN for growth hormone deficiency diagnosis, and a diazepam buccal film using PharmFilm technology for seizure clusters. The pipeline includes six new chemical entities, with elamipretide for the ultra-rare Barth syndrome under regulatory progression following an MHRA Paediatric Investigational Plan submission in December 2024.

The company commercialises through a capital-light asset model, relying on Contract Manufacturing Organisations for production and a mix of Third-Party Logistics providers, local specialist distributors, Contract Sales Organisations and regional channel partners (such as Er-Kim in Eastern Europe and Echo Therapeutics in Australia) for distribution and promotion. It claims active presence in more than 160 markets with 13 offices across the UK (Basildon HQ plus a new London office), Germany, Netherlands, Belgium, Switzerland, Italy, Denmark, Turkey, the UAE (Dubai), Australia, India (Vadodara product development centre plus Mumbai), Singapore, South Korea, and the United States. Notable transactions include the 2023 acquisition of an 11-brand CNS portfolio from Sanofi, the November 2024 licensing of catumaxomab from Lindis Biotech (leading to a December 2025 Germany launch), and the January 2025 Asia Pacific in-licensing of abaloparatide from Radius Health.

Revenue is generated through a mix of one-time licensing transactions, licensing/royalties on in-licensed specialty assets, and product sales of established brands distributed through wholesalers and partners. The company does not publicly disclose pricing details, revenue figures, or detailed ownership percentages. With more than 300 specialists globally and a leadership team substantially refreshed in 2025-2026 (including CEO Stephan Eder from Stada), Pharmanovia positions itself as a mid-sized specialty pharma platform leveraging commercial infrastructure, regulatory expertise, and a disciplined BD/licensing/M&A framework to extend the lifecycle of established medicines and accelerate the launch of specialty assets across EMEA and APAC.

Name

Pharmanovia

Legal name

Atnahs Pharma UK Limited

Website

https://pharmanovia.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Pharmanovia is a global specialty pharmaceutical company that in-licenses and commercialises innovative specialty medicines while lifecycle-managing more than 30 trusted established brands across endocrinology, neurology, cardiovascular and oncology, serving patients and healthcare providers in more than 160 markets.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Specialty pharmaceuticals
• Pharmaceutical licensing
• Branded medicines
• Drug commercialization
• Established brands

Headquarters

HQ city

Basildon

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Commercialization of established brands: Pharmanovia revitalizes, extends and expands lifecycle of established medicines. They manage a broad portfolio of trusted established brands which provide important patient treatment options today across endocrine, neurological, cardiovascular and oncological conditions.
2. Specialty pharmaceutical products: Bringing innovative specialty medicines to patients through acquisitions and licensing deals. Focus on launching and commercializing specialty pharma products in EMEA region with local execution rooted in insight and partnership.
3. New chemical entity licensing: Identification and development of new chemical entities that complement existing portfolio to address unmet need. 6 NCEs in pipeline as of April 2026.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Pharmanovia is a global specialty pharmaceutical company that acquires, revitalises and commercialises a portfolio of branded prescription medicines across more than 160 markets. The company operates two complementary engines: bringing innovative specialty medicines to market through in-licensing and acquisitions, and managing a broad portfolio of trusted established brands in endocrinology, neurology, cardiovascular and oncology. Manufacturing is outsourced to Contract Manufacturing Organisations (CMOs) and distribution is delivered via 3PLs and Contract Sales Organisations (CSOs).

Product overview

Pharmanovia is a global specialty pharmaceutical company focused on two main areas: innovative specialty medicines and trusted established brands. The specialty portfolio includes novel treatments like Korjuny (catumaxomab) for malignant ascites, abaloparatide for osteoporosis, cariprazine for schizophrenia, elamipretide for Barth syndrome, and diazepam buccal film for epilepsy. The established brands portfolio encompasses over 30 trusted brands across therapeutic areas including endocrinology, neurology, cardiovascular, and oncology. The company operates across more than 160 markets globally.

Differentiator

Problem solved

Functional benefit

Brands

• Korjuny (catumaxomab): First-in-class treatment for malignant ascites, a rare and debilitating complication of advanced-stage cancer
• TYMLOS (abaloparatide)
• Sunosi
• GHRYVELIN (macimorelin)
• Xadago
• Reagila (cariprazine)
• Valium
• Diazepam Buccal Film
• Synacthen
• Inderal
• Rocaltrol
• Bonviva
• Kytril
• Bondronat
• Dipentum
• Naprosyn
• Anaprox
• Toradol
• Famvir
• Leustatin

Products and services

• Korjuny (catumaxomab) First-in-class trifunctional T-cell engaging bispecific antibody for the treatment of malignant ascites in adults with EpCAM-positive carcinomas who are not eligible for systemic anticancer therapy; licensed from Lindis Biotech for Europe.
• Abaloparatide (TYMLOS) Human parathyroid hormone related peptide analogue indicated for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; in-licensed from Radius Health for Asia Pacific.
• Reagila (cariprazine) Third-generation atypical antipsychotic indicated for the treatment of schizophrenia in adult patients; commercialised by Pharmanovia in Australia and New Zealand.
• Elamipretide Investigational mitochondrial protective agent being developed for the treatment of Barth syndrome, an ultra-rare mitochondrial disease; in-licensed from Stealth BioTherapeutics, with a Paediatric Investigational Plan submitted to the MHRA in December 2024.
• Diazepam Buccal Film (Libervant) Patented diazepam buccal film using PharmFilm technology for acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients; in-licensed from Aquestive Therapeutics.
• Xadago (safinamide) Treatment for Parkinson's disease; acquired rights for Australia and New Zealand.
• Sunosi (solriamfetol) Treatment for wakefulness in patients with narcolepsy or obstructive sleep apnea; in-licensed from Axsome Therapeutics for EMEA, with Er-Kim as exclusive distributor in Eastern Europe.
• GHRYVELIN (macimorelin) First and only orally administered approved medicine for the diagnosis of growth hormone deficiency in adults; in-licensed from Aeterna Zentaris.
• Established Brands Portfolio Portfolio of more than 30 trusted established prescription medicines across endocrinology, neurology, cardiovascular and oncology therapeutic areas, including Dipentum, Anaprox, Naprosyn, Toradol, Bondronat, Bonviva, Kytril, Famvir, Synacthen, Inderal, Tenoretic, Tenormin, Zestoretic, Zestril, Rocaltrol, Valium and Leustatin; sourced via acquisitions from Roche, UCB, Novartis, AstraZeneca, J&J, Sanofi and Mallinckrodt.

Quantifiable outcome

• Catumaxomab (Korjuny) reduces the need for invasive procedures (paracentesis) and improves quality of life for malignant ascites patients
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

13 partnerships are on record, tiered minor and core.

• CNX TherapeuticsminorChannel Partner/ Reseller/ Distributor · 1 April 2026CNX Therapeutics acquired Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia on April 1, 2026. The product is used in hospital settings to prevent organ rejection in liver, kidney, and heart transplant patients. Commercial launch planned across Germany, France, Spain, with UK to follow.
• CSL SeqirusminorChannel Partner/ Reseller/ Distributor · 1 April 2025Acquisition of rights to Reagila (cariprazine) from CSL Seqirus in Australia and New Zealand. Gedeon Richter remains Marketing Authorisation holder. Pharmanovia takes responsibility for commercial activity in the region.
• Er-KimminorChannel Partner/ Reseller/ Distributor · 21 February 2025Exclusive distribution agreement with Er-Kim for Sunosi in Eastern Europe.
• Radius HealthcoreStrategic or Co-development Partner · 2 January 2025Exclusive in-licensing agreement for abaloparatide (marketed as TYMLOS in US) for treatment of osteoporosis. Pharmanovia responsible for clinical, regulatory and commercial activities across key Asia Pacific markets including China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines.
• Lindis BiotechcoreStrategic or Co-development Partner · 19 November 2024Partnership to commercialize catumaxomab (Korjuny), a first-in-class trifunctional bispecific monoclonal antibody for treatment of malignant ascites. Lindis granted Pharmanovia exclusive rights to bring catumaxomab to market and lead all activities to launch across Europe. Catumaxomab received European marketing authorisation approval in February 2025 and was launched in Germany in December 2025.
• Echo TherapeuticsminorChannel Partner/ Reseller/ Distributor · 20 May 2024Agreement for promotional activities in Australia for Pharmanovia's Pain/CNS portfolio and selected products within the endocrinology portfolio. Echo Therapeutics conducts promotional activities while distribution and supply arrangements remain unchanged.
• IRDiRC (International Rare Disease Research Consortium)minorStrategic or Co-development Partner · 1 November 2023Pharmanovia joined IRDiRC task force to publish drug repurposing guidebook aimed at improving care for people living with rare disease. Guidebook published in Nature Reviews Drug Discovery. Task force committed to supporting 1,000 new therapies for rare diseases to be approved by 2027.
• Stealth BioTherapeuticscoreStrategic or Co-development Partner · 30 May 2023New chemical entity licensing agreement to market and further develop elamipretide, a potential novel treatment for Barth syndrome (ultra-rare mitochondrial disease). Pharmanovia submitted Paediatric Investigational Plan to MHRA in December 2024.
• Aeterna ZentariscoreStrategic or Co-development Partner · 22 March 2023Exclusive licensing agreement for GHRYVELIN (macimorelin), the first and only orally administered approved medicine for diagnosis of growth hormone deficiency in adults.
• Axsome TherapeuticscoreStrategic or Co-development Partner · 1 January 2023Exclusive in-license agreement for Sunosi across Europe, Middle East and North America (MENA) regions.
• Aquestive TherapeuticscoreStrategic or Co-development Partner · 1 September 2022Expanded exclusive licence and supply agreement for patented diazepam buccal film formulation (Libervant) using PharmFilm technology. Initially for EU and MENA, expanded to include rest of world excluding US, Canada and China. For acute treatment of intermittent stereotypic episodes of frequent seizure activity in epilepsy patients.
• International Health Partners (IHP)minorOthers · 1 January 2022Partnership with global health NGO supporting people in disaster-hit and vulnerable communities to access vital medicines. During 2025, provided donations of critical medicines for Zanzibar to support ongoing cardiovascular care programme.
• HIPZ (Health Improvement Programme Zanzibar)minorOthers · 1 January 2021Global charity partnership established in 2021 to help strengthen healthcare infrastructure in Zanzibar and improve access to essential medicines and treatment for underserved communities. Pharmanovia has helped train healthcare professionals, provide life-saving equipment and deliver critical medicines.

Scale indicators9 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• STADA Arzneimittel: German specialty/generics pharma backed by Bain Capital and Cinven that acquires and revitalizes off-patent and specialty brands across Europe. Closest structural peer to Pharmanovia with similar asset-light European commercialization platform and PE-backed growth strategy.
• Almirall: Spanish specialty pharma focused on dermatology and specialty medicines with strong European commercialization capabilities. Comparable in business model emphasis on specialty pharma lifecycle management and geographic focus on Europe.
• Mallinckrodt: US specialty pharma focused on autoimmune and severe diseases with established brand management capabilities. Comparable in focus on specialty/established brand portfolio and lifecycle management of differentiated therapies.
• Hikma Pharmaceuticals: Jordanian-headquartered specialty and generics pharma with significant presence in MENA, US, and Europe. Comparable in geographic diversification strategy, branded and specialty portfolio, and MEA commercial focus.
• Lupin: Indian specialty generics pharma with global commercial presence including Europe and emerging markets. Comparable in specialty brand lifecycle management and global out-licensing/in-licensing activity.
• Aspen Pharmacare: South African specialty and branded generics pharma with global reach including Europe and emerging markets. Comparable model of acquiring and commercializing brands divested by multinational pharma across multiple geographies.
• Kyowa Kirin: Japanese specialty pharma with strong rare disease and biologics pipeline. Comparable in niche specialty focus, biologics like catumaxomab, and in-licensing model for assets outside core geographies.
• Recordati: Italian specialty pharma with leading rare disease franchise and established European commercialization. Comparable in therapeutic breadth (cardiology, urology, rare diseases) and specialty pharma focus.

Broad incumbents

• Viatris: Global specialty/generics giant formed from Mylan and Pfizer's Upjohn. Comparable in established brand portfolio and global commercialization, but operates at materially larger scale across broader therapeutic areas.
• Teva Pharmaceutical: Global specialty and generics leader with extensive CNS franchise including therapeutic areas overlapping with Pharmanovia's portfolio (e.g., schizophrenia, Parkinson's). Operates at vastly larger scale across broader geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pharmanovia

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmanovia